Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management. - Werner JM; Gödel P; Galldiks N; Krone C; Schroeter M; Holtick U; Flümann R; Wunderlich G; Hallek M; Fink GR; Scheid C; Onur OA; et al. (HemaSphere, 2026)